| Drug Name: | Ibuprofen (15687-27-1) |
|---|---|
| PubChem ID: | 3672 |
| SMILES: | CC(C)CC1=CC=C(C=C1)C(C)C(=O)O |
| InchiKey: | HEFNNWSXXWATRW-UHFFFAOYSA-N |
| Therapeutic Category: | Analgesics, Anti-Inflammatory Agents, Antirheumatic Agents, Central Nervous System Agents, Cyclooxygenase Inhibitors, Enzyme Inhibitors, Peripheral Nervous System Agents, Sensory System Agents |
| Molecular Weight (dalton) | : | 206.285 |
| LogP | : | 3.0732 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 1 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 37.3 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Acetaminophen (103-90-2) | Toxicity Renal | Additive | Not Established | Renal effects of over-the-counter analgesics |
| Tacrine (321-64-2) | Delirium | Additive | Unknown | Delirium caused by tacrine and ibuprofen interaction |
| Acetylsalicylic acid (50-78-2) | Gastrointestinal Hemorrhage | Antagonistic | Aspirin irreversibly blocks the production of thromboxane A2 by binding to COX-1 in platelets, and so inhibits platelet aggregation. Ibuprofen also have this effect, but it is more short-lived since they bind reversibly. Therefore competitively inhibit the binding of aspirin to platelets. When Ibuprofen is present in sufficient quantit and a daily low-dose of aspirin is given, then reduce its antiplatelet effect | Effect of ibuprofen on cardioprotective effect of aspirin |
| Methotrexate (59-05-2) | Nephrotoxicity | Synergistic | The NSAIDs as a group inhibit the synthesis of the prostaglandins (PGE2) resulting in a fall in renal perfusion, which could lead to a rise in serum methotrexate levels | Serious methotrexate toxicity caused by interaction with ibuprofen |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Haemorrhagic Infarction | Myeloperoxidase precursor (P05164) | MPO can be used as a sensitive and quantitative marker of polymorphonuclear leukocytes (PMN) accumulation into an evolving myocardial infarction (MI)@and pretreatment with ibuprofen increased the incidence of haemorrhagic infarction. [ ADR Type 3 ] | Myeloperoxidase activity as a quantitative marker of polymorphonuclear leukocyte accumulation into an experimental myocardial infarct--the effect of ibuprofen on infarct size and polymorphonuclear |
| Ibuprofen Inhibition | Arylamine N-acetyltransferase 2 (P11245) | Ibuprofen inhibition of Arylamine n-acetyltransferase activity and ibuprofen inhibition of growth in the bacterium H. pylori. [ ADR Type 1 ] | Ibuprofen affects arylamine N-acetyltransferase activity in Helicobacter pylori from peptic ulcer patients |
| Ventricular Fibrillation | Myeloperoxidase precursor (P05164) | MPO can be used as a sensitive and quantitative marker of polymorphonuclear leukocytes (PMN) accumulation into an evolving myocardial infarction (MI)@and pretreatment with ibuprofen increased the incidence of ventricular fibrillation [ ADR Type 3 ] | Myeloperoxidase activity as a quantitative marker of polymorphonuclear leukocyte accumulation into an experimental myocardial infarct--the effect of ibuprofen on infarct size and polymorphonuclear |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category